Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the ...

Agamree targets DMD and has so far generated $46 million in its first 10 months, which does attest to its strong growth potential. However, Fycompa still faces generic competition starting May 2025.

Dario Eklund, CEO of Santhera said: "The year 2024 has been a transformational year for Santhera as we strengthened our financial position and advanced the commercial roll out of AGAMREE ...

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement. The deal means that Agamree (vamorolone) will be available to ...

“Our record 2024 performance is a reflection of Catalyst’s successful launch of AGAMREE and our continued outstanding commercial capabilities that fuel the momentum of our existing products ...

The fourth quarter alone saw revenues of $141.8 million, marking a 28.3% increase from the previous year, attributed to sustained growth in existing products and the successful launch of AGAMREE.

Revenues generated from the sale of the newly launched muscle disease drug, Agamree (vamorolone), also contributed to the top line. The stock gained 5.9% in the after-market hours on Feb. 27 as ...

Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global ...

“Our record 2024 performance is a reflection of Catalyst’s successful launch of AGAMREE and our continued outstanding commercial capabilities that fuel the momentum of our existing ...